DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma patient populations covering 171 countries and more than…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Postoperative pain is one of the key segments comprising the larger market for acute pain therapies. It has experienced strong growth over the past decade owing to the uptake of Pacira BioSciences…
MARKET OUTLOOK The major depressive disorder (MDD) therapy market is mature, with numerous safe and effective treatment options available as inexpensive generics, which presents a challenge for…
Clarivate Epidemiology’s coverage of amyotrophic lateral sclerosis (ALS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
DRG Epidemiology’s coverage of tuberous sclerosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment…
For the 3.8 million people in the United States with Alzheimer’s disease (AD) dementia, approved pharmacotherapy is limited to only modestly effective procognitive symptomatic agents (e.g.,…
With a drug-treated population of about 2.5 million people in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a…
Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes (T2D) drugs and dominate the early lines of therapy before disease progression requires insulin replacement. The…
Clarivate Epidemiology’s coverage of generalized anxiety disorder (GAD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States,…
MARKET OUTLOOK Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction, which is characterized by muscle weakness and fatigue…
DRG Epidemiology's coverage of juvenile idiopathic arthritis (JIA) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United…
MARKET OUTLOOK Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. Historically, treatment of pediatric CD would begin with safe, albeit often…
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…